Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer

Lei Zhang,Ziyi Li,Katarzyna M. Skrzypczynska,Qiao Fang,Wei Zhang,Sarah A. O’Brien,Yao He,Lynn Wang,Qiming Zhang,Aeryon Kim,Ranran Gao,Jessica Orf,Tao Wang,Deepali Sawant,Jiajinlong Kang,Dev Bhatt,Daniel Lu,Chi-Ming Li,Aaron S. Rapaport,Kristy Perez,Yingjiang Ye,Shan Wang,Xueda Hu,Xianwen Ren,Wenjun Ouyang,Zhanlong Shen,Jackson G. Egen,Zemin Zhang,Xin Yu
DOI: https://doi.org/10.1016/j.cell.2020.03.048
IF: 64.5
2020-04-01
Cell
Abstract:Single-cell RNA sequencing (scRNA-seq) is a powerful tool for defining cellular diversity in tumors, but its application toward dissecting mechanisms underlying immune-modulating therapies is scarce. We performed scRNA-seq analyses on immune and stromal populations from colorectal cancer patients, identifying specific macrophage and conventional dendritic cell (cDC) subsets as key mediators of cellular cross-talk in the tumor microenvironment. Defining comparable myeloid populations in mouse tumors enabled characterization of their response to myeloid-targeted immunotherapy. Treatment with anti-CSF1R preferentially depleted macrophages with an inflammatory signature but spared macrophage populations that in mouse and human expresses pro-angiogenic/tumorigenic genes. Treatment with a CD40 agonist antibody preferentially activated a cDC population and increased <em>Bhlhe40</em><sup>+</sup> Th1-like cells and CD8 <sup>+</sup> memory T cells. Our comprehensive analysis of key myeloid subsets in human and mouse identifies critical cellular interactions regulating tumor immunity and defines mechanisms underlying myeloid-targeted immunotherapies currently undergoing clinical testing.
cell biology,biochemistry & molecular biology
What problem does this paper attempt to address?